Abstract:e15131 Background: Lung cancer and chronic obstructive pulmonary disease (COPD) often coexist. Lots of clinical and genomic descriptions related lung cancer have been investigated. However, the clinical and genomics characteristics of lung cancer coexisting COPD are still unclear. Herein, we explored the clinical characteristics and somatic mutational landscape of lung cancer coexisting COPD (COPD-LC) and compared with non-COPD Lung cancer (non-COPD-LC). Methods: We retrospectively collected total COPD-LC and non-COPD-LC patients who performed next generation sequencing (NGS) simultaneously from The Traditional Chinese Medicine Hospital Affiliated to Xinjiang Medical University during December 2018 to August 2021. And collected COPD-LC data from TCGA to further analysis. COPD was defined as incompletely reversible airflow obstruction associated with post-bronchodilator forced expiratory volume in one second (FEV1) and its ratio to forced vital capacity (FEV1/FVC) < 0.7. Results: Of the 139 patients enrolled in the study, 51 were categorized as COPD and 88 as non-COPD. In our clinical cohort, compared with non-COPD-LC, amount of male gender, older age and smoking patients were significantly higher than non-COPD in term of clinical data (all P < 0.01). As for somatic mutation in our cohort, compared with non-COPD-LC, COPD-LC had higher mutation frequency of LRP1B (43% vs 9%, P = 0.001), EPHA5 (24% vs 1%, P = 0.002), PRKDC (14% vs 1%, P = 0.039) and PREX2 (14% vs 0%, P = 0.012), which had relationship with improved tumor immunity. Immunotherapy biomarker of PD-L1 positive expression (62.5% vs 52.0%, P = 0.397) and TMB (P = 0.004) also were higher in COPD group. Whereas, COPD-LC had lower frequency of EGFR (19% vs 50%, P = 0.013). And survival analysis showed in EGFR mutant patients with targeted therapy, COPD-LC had worse PFS than non-COPD-LC (HR = 3.52, 95%CI: 1.27-9.80, P = 0.01). TCGA cohort mutation data differed from the results of our cohort. In addition, RNA data from TCGA indicated COPD-LC increased tumor immunity. Conclusions: In our research, COPD-LC had unique clinical and molecular features. High PD-L1 expression and TMB indicated these patients may benefit from immunotherapy. Notably, mutation difference between Chinese and TCGA cohort and COPD-LC immunotherapy efficacy need prospective further study.

Analysis of clinical characteristics and prognosis of lung cancer patients with CPFE or COPD: a retrospective study

Clinical characteristics and outcomes of lung cancer patients with combined pulmonary fibrosis and emphysema: a systematic review and meta-analysis of 13 studies.

Meta-analysis: clinical features and treatments of lung cancer in combined pulmonary fibrosis and emphysema

Lung Cancer in Patients with Combined Pulmonary Fibrosis and Emphysema Revisited with the 2015 World Health Organization Classification of Lung Tumors.

Combined pulmonary fibrosis and emphysema: a retrospective analysis of clinical characteristics, treatment and prognosis

Computed Tomography Characterization of Emphysema in Combined Pulmonary Fibrosis and Emphysema (CPFE) and Its Correlation with Lung Cancer with Comparison to Chronic Obstructive Pulmanory Disease (COPD)

Podoplanin-positive Cancer-Associated Fibroblasts Predict Poor Prognosis in Lung Cancer Patients

Clinical Features and Outcomes of Combined Pulmonary Fibrosis and Emphysema After Lung Transplantation

Combined Pulmonary Fibrosis and Emphysema Syndrome

Impact of combined pulmonary fibrosis and emphysema on lung cancer risk and mortality in rheumatoid arthritis: A multicenter retrospective cohort study

Clinical Outcomes and Risk Factor of Immune Checkpoint Inhibitors-Related Pneumonitis in Non-Small Cell Lung Cancer Patients with Chronic Obstructive Pulmonary Disease

Clinical Analysis of Chronic Obstructive Pulmonary Disease with Pulmonary Interstitial Fiberosis

Clinical and genomic characteristics of lung cancer concomitant chronic obstructive pulmonary disease (COPD).

Automated computed tomography quantification of fibrosis predicts prognosis in combined pulmonary fibrosis and emphysema in a real-world setting: a single-centre, retrospective study

Chronic Obstructive Pulmonary Disease Combined with Interstitial Lung Disease

Combined Pulmonary Fibrosis and Emphysema: A Narrative Review

Clinical Analysis of Chronic Obstructive Pulmonary Disease with Pulmonary Interstitial Fibrosis

Pulmonary fibrosis and lung cancer: an analysis of the Clinical Practice Research Datalink linked to the National Cancer Registration Dataset

Influence of the type of emphysema in the relationship between COPD and lung cancer

Immunotherapy for combined pulmonary fibrosis and emphysema with advanced lung cancer: two case reports and a concise review

Effect of combined pulmonary fibrosis and emphysema on patients with connective tissue diseases and systemic sclerosis: a systematic review and meta-analysis